Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scan study seeks suicide risk biomarker

NCT ID NCT02811198

Knowledge-focused Sponsor: Unity Health Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked for biological markers of suicide risk in 97 adults with major depressive disorder. Researchers used brain scans to measure how participants respond to pain, reward, and attention. The goal was to find stable brain-based signs that could help identify those at higher risk for suicide.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a brain-based test to help identify people with depression who are at higher risk for suicide.
What could go wrong
This is an early observational study with only 97 participants. The findings may not apply to everyone and need much more testing before any practical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

97 people

The number who actually took part.

Started

Jan 2017

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects will recruited from Mental Health Clinics at St. Michael's Hospital from Mood Disorders Clinics, University Health Networks (UHN) hospitals, and self-referrals from advertisements in Mental Health Department, and on social media.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. DSM-5 criteria for Major Depressive Episode within a MDD, confirmed through MINI diagnosis104 2. Ages between 18 and 70 years 3. Hamilton Depression Rating Scale - 17 item (HAMD-17) \>= 14 4. Capable of giving informed consent 5. Groups 1 and 2 participants only: HAMD-17 item 3 (suicide) \>= 2 6. Group 2 participants only: positive history of a suicide attempt within the last six months 7. Group 3 participants only: positive history of a lifetime suicide attempt Exclusion Criteria: 1. Pregnancy/lactation 2. Medical condition requiring immediate investigation or treatment 3. Recent (\< 6 months)/current history of drug abuse/dependence (other than caffeine, or nicotine) 4. Lifetime history of psychosis, Bipolar I or Bipolar II; other Axis I comorbidities are allowable 5. Individuals who are taking a daily sedative hypnotic, atypical antipsychotic or stimulant must be on a stable dose for at least 4 weeks prior to the neuroimaging scan. The dose must not be taken after 10:00pm the evening prior to the scan. Those receiving a benzodiazepine or an atypical antipsychotic on an "as needed" basis (taken, but not every day) will be washed out of their benzodiazepine/atypical antipsychotic for two weeks prior to neuroimaging. Those receive stimulants on an "as needed" basis will be washed out for 1-3 days prior to neuroimaging, depending on the stimulant half-life. 6. Participation in experimental treatment trials for the study duration.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder Suicidal Ideation Suicide

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder Suicidal ideation Suicide

Contacts and locations

Locations

  • Sakina Rizvi

    Toronto, Ontario, M5B1M8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.